DelveInsight's "Degenerative Disc Disease (DDD) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Degenerative Disc Disease (DDD) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report also covers emerging drugs, current treatment practices, Degenerative Disc Disease (DDD) market shares of the individual therapies, a detailed current Degenerative Disc Disease (DDD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Degenerative Disk Disease (DDD- osteochondrosis intervertebralis) is a common disorder that is characterized by progressive degeneration of the intervertebral disc; rendering them deformed and mechanically dysfunctional. It is a catchall phrase for a number of structural changes of the spine, such as loss of disc height, disc bulges, hydration, and impingement of nerves in the spine, among others. Degenerative Disc Disease (DDD) can be diagnosed through imaging tests like X-ays, a magnetic resonance imaging scan (MRI), or computed tomography (CT) scan which can get a better look at the discs and bony structure.
Degenerative Disc Disease (DDD) Market Key Facts
- As per the study conducted by Bruin et al. (2018), Degenerative changes were found in 456/648 patients (70.4%). Degenerated discs and Schmorls nodes had the highest prevalence and were present in 278/648 patients (42.9%) and 238/648 patients (36.7%), respectively.
- As per the study conducted by Brinjikji et al. (2014), the prevalence of disk degeneration in asymptomatic individuals increased from 37% of 20-year-old individuals to 96% of 80-year-old individuals. Disk bulge prevalence increased from 30% of those 20 years of age to 84% of those 80 years of age. Disk protrusion prevalence increased from 29% of those 20 years of age to 43% of those 80 years of age. The prevalence of annular fissure increased from 19% of those 20 years of age to 29% of those 80 years of age.
Degenerative Disc Disease (DDD) Market Growth
The Degenerative Disc Disease (DDD) Market Size is expected to increase during the forecast period owing to the increasing incident pool, rising funding, clinical trials of degenerative disk disease, and expected entries of emerging therapies in the 7MM. The advances in understanding cell biology will contribute to the development of novel therapeutics for degenerative disk disease and also to the growth of the market.
The Degenerative Disc Disease (DDD) market analysis section of the report helps to understand the current and forecasted Degenerative Disc Disease (DDD) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Degenerative Disc Disease (DDD) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The dynamics of the Degenerative Disk Disease (DDD) market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. Some of the key players are involved in developing drugs for Degenerative Disk Disease (DDD) and associated conditions. The companies marking drugs in the pipeline are mostly focused on minimally invasive regenerative medicine with the use of advanced technologies in order to gain substantial treatment modalities by focusing on disc regeneration. The pipeline for degenerative disk disease brings a positive ray of hope for potential treatment options in the market in the upcoming years. The current scenario also anticipates a positive shift in the market in the coming years.
Degenerative Disc Disease (DDD) Companies
- AnGes
- DiscGenics
- Kuros Biosciences
- Mesoblast
- Ankasa Therapeutics
- Biorestorative Therapies
- Mesoblast/Gruenthal
And many others.
Degenerative Disc Disease (DDD) Therapies covered in the report include IDCT, Fibrin-PTH (KUR-113), ART352-L, BRTX-100, AMG0103, Rexlemestrocel, and many more.
Degenerative Disc Disease (DDD) Market Drivers
- Rich emerging pipeline
- Increasing Incidence of Degenerative Disc Disease (DDD)
- Increasing cause of low back pains & neck pain in adults
- Increasing geriatric population
Degenerative Disc Disease (DDD) Epidemiology Forecast
Degenerative Disc Disease (DDD) Epidemiology Segmentation
- Total Prevalent Cases of Degenerative Disk Disease
- Total Prevalent Cases of Chronic low back pain
- Diagnosed Cases of Degenerative Disk Disease
- Treated Cases of Degenerative Disk Disease
- Age-specific Cases and Gender-specific Cases of Degenerative Disk Disease
- Severity-specific Cases of Degenerative Disk Disease
The Degenerative Disc Disease (DDD) epidemiology section covers insights about historical and current Degenerative Disc Disease (DDD) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Degenerative Disc Disease (DDD) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Degenerative Disc Disease (DDD) Market Growth